From Bench to Bedside Is No Longer Enough

In life sciences, ‘bench to bedside’ has long been the shorthand for progress: moving promising science from discovery to development to patient care.

But today, that is no longer enough.

The challenge facing life sciences leaders is not simply how to advance innovation. It is how to ensure that innovation succeeds in the real world — clinically, commercially, and operationally — for every end user involved in bringing it to life.

Because a therapy, diagnostic, device, or support program does not succeed on science alone. It succeeds when the ecosystem around it is designed to support adoption at scale: when healthcare providers receive relevant, timely engagement; when field teams can execute with clarity; when patients can access and navigate the journey with less friction; and when internal teams are working from connected processes, data, and workflows instead of fragmented systems.

That is where many organizations are still getting stuck.

For years, life sciences has talked about patient-centricity. And rightly so. But many organizations still treat adoption as a downstream issue — something to solve after development, closer to launch, or once the product is already in market.

That is the strategic mistake.

In today’s market, adoption is not just a patient-experience issue. It is a commercialization issue. If HCP engagement, field execution, patient services, and internal workflows are not connected early, organizations do not just create friction — they slow uptake, weaken launch performance, and leave revenue on the table.

Because by the time patient engagement, HCP experience, field readiness, access workflows, and commercialization planning are being addressed, many of the decisions that shape success have already been made. Teams are left managing handoffs instead of building alignment. Commercial organizations are asked to drive uptake around gaps they did not create. Patient support teams are expected to smooth over complexity. And internal stakeholders are left stitching together fragmented systems in an effort to deliver one coherent experience.

The result is familiar: friction at launch, inconsistent engagement, unnecessary burden on teams, and missed opportunities to build trust and adoption earlier.

In an environment where teams are being asked to personalize engagement, support omnichannel execution, and do more with data and AI, that fragmentation becomes even more costly.

The better approach is to design for adoption sooner.

That means considering the patient earlier — not as the final recipient of innovation, but as a critical design input. It means considering the HCP earlier, understanding what information will be meaningful, what experience will feel relevant, and what will reduce burden rather than add to it. It means considering field, commercial, and medical teams earlier, so they are not forced to compensate for poor visibility, disjointed workflows, or systems that do not reflect how modern engagement actually happens. And it means considering the internal operational teams earlier, because they are often the ones holding the entire experience together behind the scenes.

In other words, innovation should not just move from bench to bedside. It should be built from the beginning with real-world adoption in mind.

This is where I believe the conversation in life sciences needs to go next.

Not away from science. Not away from patient focus. But beyond the assumption that if innovation reaches the market, adoption will somehow follow.

It will not — at least not consistently, not efficiently, and not without cost.

Real impact happens when innovation is not only developed, but operationalized for the people who must engage with it, explain it, prescribe it, deliver it, support it, and ultimately benefit from it. That is what turns innovation into adoption — and adoption into growth.

That requires a broader view of the lifecycle — one that connects concept, development, commercialization, and engagement much earlier. It requires organizations to think beyond launch readiness and ask better questions upstream:

• What will this experience look like for the patient?
• What will the HCP need in order to understand, trust, and adopt it?
• What will the field team need in order to communicate value clearly and execute consistently?
• What will patient services and access teams need in order to reduce friction?
• What will internal teams need in order to support one connected experience across the lifecycle?
• And what barriers are we building now that others will be forced to work around later?

The organizations that answer those questions sooner will be better positioned to move faster, align more effectively, reduce friction, and create stronger outcomes for everyone involved.

We see where life sciences organizations are getting stuck — and we help build the operational, commercial, and engagement infrastructure to move them forward.

At EHG, we support life sciences organizations across the full lifecycle, from concept through commercialization and patient engagement. We help teams build the connected operational, commercial, and patient-facing foundation needed to support launch readiness, field execution, HCP engagement, patient services, and real-world impact.

Because getting to bedside matters.

But designing for adoption, engagement, and growth from the beginning matters just as much.

If your organization is looking to better connect innovation, commercialization, field execution, and patient engagement across the lifecycle, let’s connect.